The purpose of this acquisition is to enhance the shared research capabilities of the national cancer institute (NCI), center for cancer research (CCR), by acquiring an element biosciences AVITI24…
Active Purchase Order Awarded
- Contract number
- 140D0426P0333
- Awardee
-
Element Biosciences, Inc. UEI CZ2CHES131A5
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $315,090
Award facts
- Opportunity
-
- Element Biosciences AVITI¿ 24 sequencing and spati Solicitation · 140D0426Q0826 · Posted Aug 11, 2026
- Contract value 100% obligated
- $315,090.00 Current and potential, with all options
- Completion date 11% complete
- Current and potential, with all options
- Funding agency
- National Cancer Institute National Institutes of Health, Department of Health and Human Services
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Other statutory authority
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a purchase order to Element Biosciences, Inc. for an AVITI24 Sequencing and Spatial Biology System valued at $315,090 on September 23, 2026. No set-aside was used. The Interior Business Center procured the system on behalf of the NCI's Center for Cancer Research under FAR 12.201-1 (sole-source, firm fixed-price). Performance of manufacture occurs in San Diego, California; delivery and installation occur at the NCI Main Campus in Bethesda, Maryland. The system integrates next-generation sequencing, high-resolution imaging, spatial cytoprofiling, and direct in situ sequencing on a single instrument, supporting flexible configurations across multiple flow cell formats and highly multiplexed applications including RNA profiling, protein detection, mutation analysis, and immune receptor profiling. The purchase includes hardware, optics, computing components, software licenses, accessories, manufacturer warranty, and manufacturer-authorized training within one week of installation. Payment is due upon delivery, installation, and Government acceptance. Ultimate completion date is September 22, 2027.
Description
The purpose of this acquisition is to enhance the shared research capabilities of the national cancer institute (NCI), center for cancer research (CCR), by acquiring an element biosciences AVITI24 sequencing system for joint operation by the CCR geno
Quick answers
Who was awarded contract 140D0426P0333?
140D0426P0333 was awarded to Element Biosciences, Inc. by Interior Business Center (Office of Policy Management and Budget) on September 23, 2026.
How much is contract 140D0426P0333 worth?
The government has obligated $315,090 on 140D0426P0333.
Which agency awarded contract 140D0426P0333?
Interior Business Center (Office of Policy Management and Budget) awarded 140D0426P0333, with funding from National Cancer Institute (National Institutes of Health).
Was contract 140D0426P0333 competed?
The extent of competition for 140D0426P0333 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award